The insider sales are too small to warrant concern. The strong Q1 earnings and raised guidance dominate the narrative. Monitor for any larger insider sales in the coming weeks, but this cluster alone does not signal a change in outlook.
PTCT drugs
PTCT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 18 $70.15entry
- T+1 · 6mo ago +0.23%α +0.88% · $70.31
- T+5 · 6mo ago −3.56%α −5.18% · $67.65
- T+20 · 5mo ago +4.45%α +2.87% · $73.27
- T+60 · 3mo ago +3.55%α −1.30% · $72.64
Price Chart
How similar events traded
Executive Summary
Two PTCT insiders, including CEO Matthew Klein, sold a combined ~$115K in open-market sales within a week of the company's strong Q1 2026 earnings report. The sales are trivial relative to the $6.0B market cap (~0.002%) and are likely routine portfolio diversification following a 47% YoY product revenue surge and raised guidance. The cluster is not informative of bearish sentiment.
Key Financial Metrics
Key Facts
- CEO Matthew Klein sold 679 shares at $73.06 for ~$50K on 2026-05-14.
- EVP & CLO Mark Elliott Boulding sold 840 shares at $78.23 for ~$66K on 2026-05-08.
- Total open-market sales: ~$115K, representing ~0.002% of PTCT's $6.0B market cap.
- CEO also received a non-cash grant of 12,500 shares on 2026-05-13.
- Q1 2026 total revenue was $273M, up 44% YoY; product revenue rose 47% YoY to $226M.
- Full-year product revenue guidance raised to $750-$850M.
- Net loss was $2.8M in Q1 2026 vs. net income of $866.6M in Q1 2025 (prior year included a large one-time gain).
Financial Impact
Insider sales of ~$115K are immaterial relative to $6.0B market cap.
Risk Factors
- Translarna revenue declined 32% YoY ($59M vs. $86M) due to generic competition.
- Emflaza revenue declined 55% YoY ($21.5M vs. $47.8M) due to generic erosion.
- Net loss of $2.8M vs. prior-year net income of $866.6M (though prior year included a large one-time gain).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PTCT-1778880045161 |
Track record
29 reports on PTCT
4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +19.01% at T+60 after the Apr 28, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.09 Now $60.97 −1.80% settles Nov 17
- Nov 16, 2026today 144 Neutral 2/10 Entry $62.10 Now $60.97 −1.82% settles Nov 17
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $63.45 Now $60.97 −3.91% settles Nov 17
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $64.14 to $64.91 Now $60.97 −4.94% ▲ +1.20% −0.12% vs SPY
- Nov 3, 202613d ago 8-K Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
- Nov 3, 202613d ago Press Release Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $68.12 to $68.97 Now $60.97 +10.50% ▼ −1.25% +0.40% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $59.97 to $60.88 Now $60.97 +1.67% ▲ +1.52% +2.00% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $63.02 to $64.46 Now $60.97 −3.25% ▲ +2.29% +2.67% vs SPY
- Oct 16, 20264w ago Insider Cluster Neutral 3/10 Entry $61.53 to $62.92 Now $60.97 −0.91% ▲ +2.26% +1.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers